TY - JOUR
T1 - National cancer institute-national heart, lung and blood institute/pediatric blood and marrow transplant consortium first international consensus conference on late effects after pediatric hematopoietic cell transplantation
T2 - Long-term organ damage and dysfunction
AU - Nieder, Michael L.
AU - McDonald, George B.
AU - Kida, Aiko
AU - Hingorani, Sangeeta
AU - Armenian, Saro H.
AU - Cooke, Kenneth R.
AU - Pulsipher, Michael A.
AU - Baker, K. Scott
N1 - Funding Information:
Financial disclosure: Funding for this work was made possible in part by the following National Institute of Health grants: 1R13CA159788-01 (MP, KSB), U01HL069254 (MP), R01 CA112530-05 [KSB]. The views expressed in this manuscript do not reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Further support was provided by a generous grant from the St. Baldrick’s Foundation and the Lance Armstrong Foundation , as well as the following pharmaceutical companies: Genzyme, Otsuka America Pharmaceutical, Inc., and Sigma-Tau Pharmaceuticals, Inc . The content is solely the responsibility of the authors and does not necessarily represent the official views of those that provided funding.
PY - 2011/11
Y1 - 2011/11
N2 - Long-term complications after hematopoietic cell transplantation (HCT) have been studied in detail. Although virtually every organ system can be adversely affected after HCT, the underlying pathophysiology of these late effects remain incompletely understood. This article describes our current understanding of the pathophysiology of late effects involving the gastrointestinal, renal, cardiac, and pulmonary systems, and discusses post-HCT metabolic syndrome studies. Underlying diseases, pretransplantation exposures, transplantation conditioning regimens, graft-versus-host disease, and other treatments contribute to these problems. Because organ systems are interdependent, long-term complications with similar pathophysiologic mechanisms often involve multiple organ systems. Current data suggest that post-HCT organ complications result from cellular damage that leads to a cascade of complex events. The interplay between inflammatory processes and dysregulated cellular repair likely contributes to end-organ fibrosis and dysfunction. Although many long-term problems cannot be prevented, appropriate monitoring can enable detection and organ-preserving medical management at earlier stages. Current management strategies are aimed at minimizing symptoms and optimizing function. There remain significant gaps in our knowledge of the pathophysiology of therapy-related organ toxicities disease after HCT. These gaps can be addressed by closely examining disease biology and identifying those patients at greatest risk for adverse outcomes. In addition, strategies are needed for targeted disease prevention and health promotion efforts for individuals deemed at high risk because of their genetic makeup or specific exposure profile.
AB - Long-term complications after hematopoietic cell transplantation (HCT) have been studied in detail. Although virtually every organ system can be adversely affected after HCT, the underlying pathophysiology of these late effects remain incompletely understood. This article describes our current understanding of the pathophysiology of late effects involving the gastrointestinal, renal, cardiac, and pulmonary systems, and discusses post-HCT metabolic syndrome studies. Underlying diseases, pretransplantation exposures, transplantation conditioning regimens, graft-versus-host disease, and other treatments contribute to these problems. Because organ systems are interdependent, long-term complications with similar pathophysiologic mechanisms often involve multiple organ systems. Current data suggest that post-HCT organ complications result from cellular damage that leads to a cascade of complex events. The interplay between inflammatory processes and dysregulated cellular repair likely contributes to end-organ fibrosis and dysfunction. Although many long-term problems cannot be prevented, appropriate monitoring can enable detection and organ-preserving medical management at earlier stages. Current management strategies are aimed at minimizing symptoms and optimizing function. There remain significant gaps in our knowledge of the pathophysiology of therapy-related organ toxicities disease after HCT. These gaps can be addressed by closely examining disease biology and identifying those patients at greatest risk for adverse outcomes. In addition, strategies are needed for targeted disease prevention and health promotion efforts for individuals deemed at high risk because of their genetic makeup or specific exposure profile.
KW - Cardiac toxicity
KW - Pediatric allogeneic transplantation
KW - Pediatric autologous transplantation
KW - Pulmonary toxicity
KW - Renal toxicity
UR - http://www.scopus.com/inward/record.url?scp=80054846946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054846946&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2011.09.013
DO - 10.1016/j.bbmt.2011.09.013
M3 - Article
C2 - 21963877
AN - SCOPUS:80054846946
SN - 1083-8791
VL - 17
SP - 1573
EP - 1584
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 11
ER -